CN106265643A - The application in preparation treatment prostate hyperplasia medicine of indole 3 methanol, di-indole methyl hydride and derivant thereof - Google Patents
The application in preparation treatment prostate hyperplasia medicine of indole 3 methanol, di-indole methyl hydride and derivant thereof Download PDFInfo
- Publication number
- CN106265643A CN106265643A CN201610653722.6A CN201610653722A CN106265643A CN 106265643 A CN106265643 A CN 106265643A CN 201610653722 A CN201610653722 A CN 201610653722A CN 106265643 A CN106265643 A CN 106265643A
- Authority
- CN
- China
- Prior art keywords
- indole
- alkoxyl
- application
- hydrogen
- methanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
The present invention proposes the application in preparation treatment prostate hyperplasia medicine of indole 3 methanol, di-indole methyl hydride and derivant thereof, such medicine can be by improving the expression of the specific gene of intracellular free radical resisting, strengthen cell and actively remove the ability of free radical, alleviate the injury of radical pair cell and tissue.Meanwhile, small-molecule drug used in the present invention is easily obtained, cheap, stable in properties, it is simple to storage and transport, has broad application prospects.
Description
Technical field
The invention belongs to biomedicine technical field, be specifically related to Indole-3-carbinol, di-indole methyl hydride and derivant thereof and exist
Application in preparation treatment prostate hyperplasia medicine.
Background technology
Prostate hyperplasia is also known as hypertrophy.Symptom mainly shows as two groups of symptoms, and a class is irritation sign of bladder;Another kind of it is
Because hypertrophy prostate blocks the obstructive symptoms that urinary tract produces.Irritation sign of bladder: frequent micturition, urgent micturition, nocturia increase and urgency
Urinary incontinence.Frequent micturition is the early signal of prostatic hyperplasia, and especially nocturia increased frequency more has clinical meaning.This disease has three mainly
Feature: prostate volume increases;Bladder outlet obstruction;There are the lower urinary tract symptoms such as dysuria, frequent micturition, urgent micturition.If it find that disease
Shape, it is proposed that go to hospital to check in time, treatment.In order to avoid delaying the state of an illness, unhealthful.
Prostate hyperplasia is one of the commonly encountered diseases of Urology Surgery, frequently-occurring disease.Operative therapy typically can be taked to treat,
But to some inoperable patients, do not find more preferable Therapeutic Method always.The Indole-3-carbinol of the present invention, two indole first
Alkane and derivant thereof have definite therapeutical effect to prostate hyperplasia, and the Drug therapy for prostate hyperplasia opens one
The therapy approach that bar is new.
Summary of the invention
It is an object of the invention to provide a kind of disease symptom that can effectively reduce prostate hyperplasia, can as treatment before
Molecule drug candidate i.e. Indole-3-carbinol, di-indole methyl hydride and the derivant thereof of row gland hypertrophic response is at preparation treatment prostate
Application in loose medicine.
The Indole-3-carbinol with structure formula (I) of the present invention and derivant thereof are in preparing prostate hyperplasia medicine
Application, adjuvant is tea pigment and lycopene, in structure formula (I), R1, R2, R4, R5, R6, R7 be respectively H, halogenic substituent,
Sulfonic group or the nitrogenous alkoxyl of C1-C10 or C1-C10 alkoxyl or C1-C10 alkyl.
Preferably, in described structure formula (I), when R1, R2, R4, R5, R6, R7 are hydrogen, the chemical combination shown in this structural formula
Thing is Indole-3-carbinol；
When R5 is the nitrogenous alkoxyl of halogenic substituent, sulfonic group or C1-C10 or C1-C10 alkoxyl or C1-C10 alkyl, R1,
R2, R4, R6, R7 are hydrogen；
When R1 is the nitrogenous alkoxyl of halogenic substituent, sulfonic group or C1-C10 or C1-C10 alkoxyl or C1-C10 alkyl, R2,
R4, R5, R6, R7 are hydrogen；
When R2 is the nitrogenous alkoxyl of halogenic substituent, sulfonic group or C1-C10 or C1-C10 alkoxyl or C1-C10 alkyl, R1,
R4, R5, R6, R7 are hydrogen；
The di-indole methyl hydride with structure formula (II) of the present invention and derivant thereof are in preparing treating organs transplant rejection medicine
Application, adjuvant is tea pigment and lycopene,
Wherein, R1, R2, R4, R5, R6, R7, R1 ', R2 ', R4 ', R5 ', R6 ', R7 ' are respectively hydrogen or halogen substituent group, sulfonic group
Or the nitrogenous alkoxyl of C1-C10 or C1-C10 alkoxyl or C1-C10 alkyl.
Preferably, in described structure formula (II), as R1, R2, R4, R5, R6, R7, R1 ', R2 ', R4 ', R5 ', R6 ', R7 '
When being hydrogen, now the compound shown in this structural formula is di-indole methyl hydride；
When R5 and R5 ' is the nitrogenous alkoxyl of halogenic substituent, sulfonic group or C1-C10 or C1-C10 alkoxyl or C1-C10 simultaneously
Alkyl, R1, R2, R4, R6, R7, R1 ', R2 ', R4 ', R6 ', R7 ' be hydrogen.
When R1 and R1 ' is the nitrogenous alkoxyl of halogenic substituent, sulfonic group or C1-C10 or C1-C10 alkoxyl or C1-simultaneously
C10 alkyl, R2, R4, R5, R6, R7, R2 ', R4 ', R5 ', R6 ', R7 ' be hydrogen
When R2 and R2 ' is the nitrogenous alkoxyl of halogenic substituent, sulfonic group or C1-C10 or C1-C10 alkoxyl or C1-C10 simultaneously
Alkyl, R1, R4, R5, R6, R7, R1 ', R4 ', R5 ', R6 ', R7 ' be hydrogen.
The Indole-3-carbinol of the present invention, di-indole methyl hydride and derivant thereof are in preparation treatment prostate hyperplasia medicine
Application, it is anti-that single compound Indole-3-carbinol or a kind of use of di-indole methyl hydride or derivatives thereof can treat repulsion
Should, then obviously, the various forms of mixtures of above-claimed cpd also can reach certain therapeutic effect.
Commercially available substituted indoles is used to be probably these compounds of acquisition to the substitutive derivative synthesizing I3C
Method easily.The derivant of DIM again may be by the method for formaldehyde condensation substituted indoles and prepares.But, the latter's is bad
Gesture is that by-product is formed such that isolated and purified required DIM derivant is increasingly complex.
Use the Indole-3-carbinol (I3C) of the present invention, di-indole methyl hydride (DIM) and derivant thereof, pharmaceutically may be used with multiple
Combine, by such as oral cavity, vein, nasal cavity, rectum or other any activity that can carry effective dose with the carrier accepted
The administering mode of material, can be prepared as various liquid preparation such as injection, oral liquid formulations etc., it is also possible to be prepared as various having
Imitate and be prone to solid preparation such as capsule, the suppository etc. being administered.Wherein, for injection or liquid preparation for oral use, needed for it
Carrier can be sterilized water, Sterile Saline or water solublity organic carrier such as cyclodextrin, Semen Maydis oil, olive oil, oleic acid second
The carrier that ester, glycols etc. are medically acceptable；Solid dosage formulation can add the conventional adjuvant of solid preparation such as in preparation
Excipient glucose, lactose, cellulose etc., also can add lubricant Polyethylene Glycol, magnesium stearate etc., and binding agent, taste masking
Adjunct ingredient needed for the solid preparations such as agent, then by operation molding such as mixing, granulations.Active matter in these preparations above-mentioned
The effective dose of matter is the amount that rejection symptom can be made substantially to reduce, and the research worker with routine techniques will can determine this item
The maximally effective dosage of the reagent that invention is provided and time consider administering mode, drug metabolism, and some other medicine
For kinetic parameter such as drug distribution, clearance rate etc..
The present invention proposes Indole-3-carbinol, di-indole methyl hydride and derivative compound thereof at preparation treatment prostate hyperplasia
New application in medicine, this medicine can strengthen cell actively by improving the expression of the specific gene of intracellular free radical resisting
Remove the ability of free radical, alleviate the injury of radical pair cell and tissue, it is possible to play rejection and stop effect.Meanwhile,
Small-molecule drug used in the present invention is easily obtained, cheap, stable in properties, it is simple to storage and transport, has wide
Application prospect.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is described further:
Embodiment 1
(5-chloro-indole-3-methanol and 5, the preparation of 5 '-dichloro di-indole methyl hydride)
0.86ml phosphoryl chloride phosphorus oxychloride is slowly added into 2.9ml pre-cool to the dimethylformamide of 0 DEG C.By 8.6mmol 5-
Chloro-indole (being purchased from Nanjing R&M Fine Chemical Co., Ltd.) is dissolved in the dimethylformamide of 1.0ml, is then slowly added into
In the phosphoryl chloride phosphorus oxychloride solution of aforementioned pre-cooling, the suspension formed heats 60 minutes at 37 DEG C, until the yellow solution of clarification becomes
Flaxen pasty mass.Then in this pasty mass, add the frozen water of 1ml, be slow added into 10ml and contain 3.75 grams of KOH
Aqueous solution.Cooling down after being heated to boiling by this mixture, filter, washing, air drying can obtain 5-chloro-indole-3-
Acetaldehyde.
1.0 grams of 5-chloro-indole-3-acetaldehyde are dissolved in 5.0ml methanol, are continuously added into solid sodium borohydride, until excessive.So
Adding 50ml water in backward reactant, be cooled to 0 DEG C, filter, lucifuge vacuum drying obtains 5-chloro-indole-3-methanol, yield
About 90%.
1.0 grams of 5-chloro-indole-3-methanol are joined in the phosphate buffer that pH is 5.5, is stirred at room temperature 6 hours, reaction
Process is monitored by thin layer chromatography (TLC).Product filters, and lucifuge vacuum drying i.e. obtains 5,5 '-dichloro two indole
Methane, yield about 85%.
Embodiment 2
(5-nitroindoline-3-methanol and 5, the preparation of 5 '-dinitro di-indole methyl hydride)
5-nitroindoline can be by commercially available acquisition (Nanjing R&M Fine Chemical Co., Ltd.).By 0.92ml phosphoryl chloride phosphorus oxychloride
It is slowly added into 2.9ml to pre-cool to the dimethylformamide of 0 DEG C.8.2mmol 5-nitroindoline is dissolved in 1.0ml
Dimethylformamide in, be then slowly added in the phosphoryl chloride phosphorus oxychloride solution of aforementioned pre-cooling, the suspension formed is 42 DEG C of heating
90 minutes, until the yellow solution of clarification becomes flaxen pasty mass.Then in this pasty mass, add the ice of 1ml
Water, is slow added into the aqueous solution that 10ml contains 3.75 grams of KOH.Cool down after being heated to boiling by this mixture, filter, washing,
Air drying can obtain 5-nitroindoline-3-acetaldehyde.
1.0 grams of 5-nitroindoline-3-acetaldehyde are dissolved in 5.0ml methanol, are continuously added into solid sodium borohydride, until excessive.
Then adding 50ml water in reactant, be cooled to 0 DEG C, filter, lucifuge vacuum drying obtains 5-nitroindoline-3-methanol,
Yield about 87%.
1.0 grams of 5-nitroindoline-3-methanol are joined in the phosphate buffer that pH is 5.5, is stirred at room temperature 6 hours, instead
Answer process to pass through thin layer chromatography (TLC) to be monitored.Product filters, and lucifuge vacuum drying i.e. obtains 5, and 5 '-dinitro is double
Indole methyl hydride, yield about 80%.
Embodiment 3
(5-amyl group Indole-3-carbinol and 5, the preparation of 5 '-diamyl-di-indole methyl hydride)
5-amyl group indole can be by commercially available acquisition (Nanjing R&M Fine Chemical Co., Ltd.).By 0.82ml phosphoryl chloride phosphorus oxychloride
It is slowly added into 2.9ml to pre-cool to the dimethylformamide of 0 DEG C.9.2mmol 5-amyl group indole is dissolved in 1.0ml
Dimethylformamide in, be then slowly added in the phosphoryl chloride phosphorus oxychloride solution of aforementioned pre-cooling, the suspension formed is 37 DEG C of heating
40-60 minute, until the yellow solution of clarification becomes flaxen pasty mass.Then in this pasty mass, add 1ml's
Frozen water, is slow added into the aqueous solution that 10ml contains 3.75 grams of KOH.Cool down after being heated to boiling by this mixture, filter, water
Washing, air drying can obtain 5-amyl group indole-3-acetaldehyde.
1.0 grams of 5-amyl group indole-3-acetaldehyde are dissolved in 5.0ml methanol, are continuously added into solid sodium borohydride, until excessive.
Then adding 50ml water in reactant, be cooled to 0 DEG C, filter, lucifuge vacuum drying obtains 5-amyl group Indole-3-carbinol,
Yield about 85%.
1.0 grams of 5-amyl group Indole-3-carbinols are joined in the phosphate buffer that pH is 5.5, is stirred at room temperature 10 hours, instead
Answer process to pass through thin layer chromatography (TLC) to be monitored.Product filters, and lucifuge vacuum drying i.e. obtains 5, and 5 '-diamyl is double
Indole methyl hydride, yield about 70%.
Embodiment 4
(N-methoxy-Indole-3-methanol and the preparation of N, N '-dimethoxy-di-indole methyl hydride)
N-methoxy-Indole can be by commercially available acquisition (Nanjing R&M Fine Chemical Co., Ltd.).By 0.86ml phosphinylidyne
Chlorine is slowly added into 2.9ml and pre-cools to the dimethylformamide of 0 DEG C.8.9mmol N-methoxy-Indole is dissolved in
In the dimethylformamide of 1.0ml, being then slowly added in the phosphoryl chloride phosphorus oxychloride solution of aforementioned pre-cooling, the suspension formed is 40
DEG C heating 60-90 minute, until clarification yellow solution become flaxen pasty mass.Then add in this pasty mass
Enter the frozen water of 1ml, be slow added into the aqueous solution that 10ml contains 3.75 grams of KOH.Cool down after being heated to boiling by this mixture,
Filtering, washing, air drying can obtain N-methoxy-Indole-3-acetaldehyde.
1.0 grams of N-methoxy-Indole-3-acetaldehyde are dissolved in 5.0ml methanol, are continuously added into solid sodium borohydride, until mistake
Amount.Then adding 50ml water in reactant, be cooled to 0 DEG C, filter, lucifuge vacuum drying obtains N-methoxy-Indole-3-
Methanol, yield about 80%.
1.0 grams of N-methoxy-Indole-3-methanol are joined in the phosphate buffer that pH is 5.5, are stirred at room temperature 12 hours,
Course of reaction is monitored by thin layer chromatography (TLC).Product filters, and lucifuge vacuum drying i.e. obtains N, N '-dimethoxy
Base bis (indolyl) methane, yield about 70%.
Embodiment 5
(1-butyl-2 methyl indole-3-methanol and 1,1 '-dibutyl-2, the preparation of 2 '-dimethyl di-indole methyl hydride)
1-butyl-2 methyl indole can be by commercially available acquisition (Nanjing R&M Fine Chemical Co., Ltd.).By 0.82ml
Phosphoryl chloride phosphorus oxychloride is slowly added into 2.9ml and pre-cools to the dimethylformamide of 0 DEG C.By 8.2mmol 1-butyl-2-methyl Yin
Diindyl is dissolved in the dimethylformamide of 1.0ml, is then slowly added in the phosphoryl chloride phosphorus oxychloride solution of aforementioned pre-cooling, and formed is outstanding
Supernatant liquid heats 90 minutes at 42 DEG C, until the yellow solution of clarification becomes flaxen pasty mass.Then to this pasty mass
The frozen water of middle addition 1ml, is slow added into the aqueous solution that 10ml contains 3.8 grams of KOH.After being heated to this mixture boiling the coldest
But, filtering, washing, air drying can obtain 1-butyl-2 methyl indole-3-acetaldehyde.
1.0 grams of 1-butyl-2 methyl indole-3-acetaldehyde is dissolved in 5.0ml methanol, is continuously added into solid sodium borohydride, directly
To excess.Then adding 50ml water in reactant, be cooled to 0 DEG C, filter, lucifuge vacuum drying obtains 1-butyl-2-methyl
Indole-3-carbinol, yield about 85%.
1.0 grams of 1-butyl-2 methyl indole-3-methanol is joined in the phosphate buffer that pH is 5.5, is stirred at room temperature 6
Hour, course of reaction is monitored by thin layer chromatography (TLC).Product filters, and lucifuge vacuum drying i.e. obtains 1,1 '-
Dibutyl-2,2 '-dimethyl bis (indolyl) methane, yield about 80%.
Embodiment 6
(4-bromo indole-3-methanol and 4, the preparation of 4 '-dibromo di-indole methyl hydride)
0.86ml phosphoryl chloride phosphorus oxychloride is slowly added into 2.9ml pre-cool to the dimethylformamide of 0 DEG C.By 8.6mmol 4-
Bromo indole (being purchased from Nanjing R&M Fine Chemical Co., Ltd.) is dissolved in the dimethylformamide of 1.0ml, is then slowly added into
In the phosphoryl chloride phosphorus oxychloride solution of aforementioned pre-cooling, the suspension formed heats 60 minutes at 37 DEG C, until the yellow solution of clarification becomes
Flaxen pasty mass.Then in this pasty mass, add the frozen water of 1ml, be slow added into 10ml and contain 3.75 grams of KOH
Aqueous solution.Cooling down after being heated to boiling by this mixture, filter, washing, air drying can obtain 4-bromo indole-3-
Acetaldehyde.
1.0 grams of 4-bromo indole-3-acetaldehyde are dissolved in 5.0ml methanol, are continuously added into solid sodium borohydride, until excessive.So
Adding 50ml water in backward reactant, be cooled to 0 DEG C, filter, lucifuge vacuum drying obtains 4-bromo indole-3-methanol, yield
About 90%.
1.0 grams of 4-bromo indole-3-methanol are joined in the phosphate buffer that pH is 5.5, is stirred at room temperature 6 hours, reaction
Process is monitored by thin layer chromatography (TLC).Product filters, and lucifuge vacuum drying i.e. obtains 4,4 '-dibromo two indole
Methane, yield about 85%.
Experimental technique
(1), this test patient by certain the People's Hospital of city provide, be provided with 120 make a definite diagnosis suffer from prostate hyperplasia patient participate in,
Age 32-65 year.
(2), test medication: respectively the product Semen Maydis oil dissolving of embodiment 1-embodiment 6 is made into 5.0mg/ml and is administered orally
Liquid storage is standby.
(3), test method: patient is administered orally, every day 2 times, and each 20g 3 weeks is a course for the treatment of, treats 4 continuously
The individual course for the treatment of.
(4), judgment criteria
Cure: prostatitis, prostate hyperplasia related symptoms are wholly absent, and make a definite diagnosis through doctor and fully recovered；
Effective: prostatitis, prostate hyperplasia related symptoms partial disappearance, it is still necessary to treat further；
Invalid: prostatitis, prostate hyperplasia related symptoms do not have any improvement, the most serious.
(5), therapeutic outcome
120 patients have 115 patients to complete experiment, have 5 example patients to come off；Wherein 57 example recovery from illness, 53 examples show
Effect, 5 examples are invalid, and cure rate is 49.6%, and total effective rate is 95.6%.
(6), conclusion
Clinical test results shows, present invention row gland hypertrophy aspect before the treatment has the most significant therapeutic effect, therefore, because of
This, the new application in preparation treatment prostate hyperplasia medicine of Indole-3-carbinol, di-indole methyl hydride and derivative compound thereof.
The foregoing is only one embodiment of the invention, be not limiting as the present invention, all employing equivalents or equivalent transformation
The technical scheme that obtained of mode, all fall within protection scope of the present invention.
Claims (10)
1. having Indole-3-carbinol and the derivant application in preparing prostate hyperplasia medicine thereof of structure formula (I), adjuvant is
Tea pigment and lycopene, in structure formula (I), R1, R2, R4, R5, R6, R7 are respectively H, halogenic substituent, sulfonic group or C1-
The nitrogenous alkoxyl of C10 or C1-C10 alkoxyl or C1-C10 alkyl.
Application the most according to claim 1, it is characterised in that: in described structure formula (I), as R1, R2, R4, R5, R6, R7
When being hydrogen, the compound shown in this structural formula is Indole-3-carbinol.
Application the most according to claim 2, it is characterised in that: R5 is that halogenic substituent, sulfonic group or C1-C10 are containing azane
Epoxide or C1-C10 alkoxyl or C1-C10 alkyl, R1, R2, R4, R6, R7 are hydrogen.
Application the most according to claim 2, it is characterised in that: R1 is that halogenic substituent, sulfonic group or C1-C10 are containing azane
Epoxide or C1-C10 alkoxyl or C1-C10 alkyl, R2, R4, R5, R6, R7 are hydrogen.
Application the most according to claim 2, it is characterised in that: when R2 is that halogenic substituent, sulfonic group or C1-C10 are nitrogenous
Alkoxyl or C1-C10 alkoxyl or C1-C10 alkyl, R1, R4, R5, R6, R7 are hydrogen.
6. the di-indole methyl hydride with structure formula (II) and the derivant thereof of the present invention is preparing treating organs transplant rejection medicine
In application, adjuvant is tea pigment and lycopene.
Application the most according to claim 6, it is characterised in that: R1, R2, R4, R5, R6, R7, R1 ', R2 ', R4 ', R5 ',
R6 ', R7 ' are respectively hydrogen or halogen substituent group, sulfonic group or the nitrogenous alkoxyl of C1-C10 or C1-C10 alkoxyl or C1-C10 alkane
Base.
Application the most according to claim 6, it is characterised in that: in described structure formula (II), when R1, R2, R4, R5, R6,
R7, R1 ', R2 ', R4 ', R5 ', R6 ', R7 ' be when being hydrogen, now the compound shown in this structural formula is di-indole methyl hydride.
Application the most according to claim 6, it is characterised in that: when R5 and R5 ' be simultaneously halogenic substituent, sulfonic group or
The nitrogenous alkoxyl of C1-C10 or C1-C10 alkoxyl or C1-C10 alkyl, R1, R2, R4, R6, R7, R1 ', R2 ', R4 ', R6 ',
R7 ' is hydrogen.
Application the most according to claim 6, it is characterised in that: when R1 and R1 ' be simultaneously halogenic substituent, sulfonic group or
The nitrogenous alkoxyl of C1-C10 or C1-C10 alkoxyl or C1-C10 alkyl, R2, R4, R5, R6, R7, R2 ', R4 ', R5 ', R6 ',
R7 ' is hydrogen；When R2 and R2 ' be simultaneously the nitrogenous alkoxyl of halogenic substituent, sulfonic group or C1-C10 or C1-C10 alkoxyl or
C1-C10 alkyl, R1, R4, R5, R6, R7, R1 ', R4 ', R5 ', R6 ', R7 ' be hydrogen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610653722.6A CN106265643A (en) | 2016-08-11 | 2016-08-11 | The application in preparation treatment prostate hyperplasia medicine of indole 3 methanol, di-indole methyl hydride and derivant thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610653722.6A CN106265643A (en) | 2016-08-11 | 2016-08-11 | The application in preparation treatment prostate hyperplasia medicine of indole 3 methanol, di-indole methyl hydride and derivant thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106265643A true CN106265643A (en) | 2017-01-04 |
Family
ID=57668276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610653722.6A Pending CN106265643A (en) | 2016-08-11 | 2016-08-11 | The application in preparation treatment prostate hyperplasia medicine of indole 3 methanol, di-indole methyl hydride and derivant thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106265643A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101138569A (en) * | 2007-08-31 | 2008-03-12 | 北京未名宝生物科技有限公司 | Pharmaceutical composition for improving curative effect of indole-3-methanol and derivant thereof |
| KR20160059029A (en) * | 2014-11-17 | 2016-05-26 | 한국식품연구원 | Composition for Prevention, Treatment or Reduction of Prostate Hyperplasia Comprising Diindolylmethane |
| CN106074504A (en) * | 2016-06-18 | 2016-11-09 | 张阳康 | The application in preparation treatment hypertrophy of the prostate medicine of indoles 3 methyl alcohol, di-indole methyl hydride and derivative thereof |
-
2016
- 2016-08-11 CN CN201610653722.6A patent/CN106265643A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101138569A (en) * | 2007-08-31 | 2008-03-12 | 北京未名宝生物科技有限公司 | Pharmaceutical composition for improving curative effect of indole-3-methanol and derivant thereof |
| KR20160059029A (en) * | 2014-11-17 | 2016-05-26 | 한국식품연구원 | Composition for Prevention, Treatment or Reduction of Prostate Hyperplasia Comprising Diindolylmethane |
| CN106074504A (en) * | 2016-06-18 | 2016-11-09 | 张阳康 | The application in preparation treatment hypertrophy of the prostate medicine of indoles 3 methyl alcohol, di-indole methyl hydride and derivative thereof |
Non-Patent Citations (2)
| Title |
|---|
| SREENIVASA R CHINNI等: "Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells", 《ONCOGENE》 * |
| 吴晶 等: "天然色素的药理作用研究概况", 《时珍国医国药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102389419A (en) | Application of indole-3-carbinol, diindolylmethane and derivatives thereof to preparation of medicine for preventing and controlling atherosclerosis | |
| CN104540501B (en) | The therapy combined for the procaspase of glioblastoma multiforme | |
| CN103502219A (en) | Novel small-molecules as therapeutics | |
| CN113461697A (en) | Chlorin compound and preparation method and application thereof | |
| CN102335168B (en) | Application of indole-3-carbinol, diindolyl methane and derivatives thereof in preparation of medicaments for treating osteoporosis | |
| CN106749478B (en) | 1,4 sensitive pH Di-substituted phthalocyanine Zn complexes and preparation method thereof and in application pharmaceutically | |
| CN106565763B (en) | Axial substituted silicon phthalocyanine complex sensitive pH and preparation method thereof and application in medicine | |
| CN103143013B (en) | Photosensitive medicinal preparation containing amino poly-carboxylic acid modification tetraphenylporphyrin compound and purpose thereof | |
| CN103040864A (en) | Medical application of selenium phosphate compound | |
| CN102327262A (en) | Indole-3-methanol, diindolylmethane and application of derivative thereof in preparation of drug for treating diabetes | |
| CN106265643A (en) | The application in preparation treatment prostate hyperplasia medicine of indole 3 methanol, di-indole methyl hydride and derivant thereof | |
| CN102429901B (en) | Application of indole-3-carbinol, diindolylmethane and derivatives thereof in preparation of medicaments for preventing and treating renal fibrosis | |
| CN107530302A (en) | MELK salicylate inhibitor and application method | |
| CN106265644A (en) | The application in preparation treatment seborrheic alopecia medicine of indole 3 methanol, di-indole methyl hydride and derivant thereof | |
| CN114230610A (en) | Radiolabel, precursor compound thereof, preparation method and application | |
| CN102335169B (en) | Application of indole-3-carbinol, diindolyl methane and derivatives thereof in preparation of medicaments for treating senile dementia | |
| CN102695503A (en) | Halogenated aliphatic carboxylic acids, oligomers and/or polymers thereof and their use in devitalizing external and internal neoplasms | |
| CN105012297A (en) | Use of indole-3-carbinol, bis-indolymethane and derivatives thereof in drugs for treatment on contact dermatitis | |
| CN102389420A (en) | Applications of indole-3-carbinol, diindolylmethane and derivatives thereof in preparation of medicaments for preventing and treating pulmonary fibrosis | |
| CN108904510A (en) | Dexamethasone is used to inhibit or treat the purposes of cancer of pancreas | |
| CN105434432B (en) | N-Hydroxyphthalimide class compound application in preparation of anti-tumor drugs | |
| CN106344564A (en) | Application of indole-3-carbinol and diindolylmethane and derivatives thereof in preparation of medicines for treating hair follicle keratosis | |
| CN103845732A (en) | Oral photosensitive drug preparation containing haematoporphyrin or haematoporphyrin iron and use | |
| CN108379587A (en) | A kind of efficient combination drug and its preparation method and application for inhibiting glioma | |
| CN111632046B (en) | Application of naphthoquinone dimer in preparation of anti-tumor metastasis drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170104 |